Study Summary
A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies
Want to learn more about this trial?
Request More InfoInterventions
CAR-T cells targeting CD19 and CD22BIOLOGICAL
Using the 3+3 design, the following dose levels will be assessed:
Dose level 1: 0.5x10e6 CAR-transduced T cells/kg; Dose level 2: 1x10e6 CAR-transduced T cells/kg; Dose level 3: 2x10e6 CAR-transduced T cells/kg; Dose level 0: 0.25x10e6 CAR-transduced T cells/kg
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University Hospital , Department of Internal Medicine II | Tübingen | Baden-Wurttemberg | Germany |
| University Hospital, Clinic for Pediatric Medicine | Tübingen | Baden-Wurttemberg | Germany |